Meeting
2017 Gastrointestinal Cancers Symposium
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).
Authors
Philippa Corrie
Addenbrooke's Hospital, Cambridge, United Kingdom
Philippa Corrie , Wendi Qian , Bristi Basu , Duncan Ian Jodrell , Stephen Falk , Chinenyu Iwuji , Harpreet Wasan , Daniel H. Palmer , Martin Scott-Brown , Jonathan Wadsley , Seema Safia Arif , A. Burcu Babaoglan , Katy Marie Dalchau , Aarthi Gopinathan , Anita Chhabra , Andrea Machin , Albrecht Neesse , David A. Tuveson , Juan W. Valle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
ISRCTN71070888
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 342)
DOI
10.1200/JCO.2017.35.4_suppl.342
Abstract #
342
Poster Bd #
F12
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Philippa Corrie
Poster
2018 Gastrointestinal Cancers Symposium
The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Daniel John Renouf
Poster
2023 ASCO Annual Meeting
FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.
First Author: Shao Zhimin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni